Stockscreener 앱 받기
30.58
0.75%
-0.23
시간 외 거래:
30.72
0.14
+0.46%
Avidity Biosciences Inc 주식(RNA)의 최신 뉴스
Avidity Biosciences Expands Team with $2.2M Stock Package: 16 New Hires Signal Growth - Stock Titan
Avidity Biosciences Target of Unusually Large Options Trading (NASDAQ:RNA) - Defense World
Stifel Financial Corp Cuts Stake in Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World
HC Wainwright Analysts Reduce Earnings Estimates for RNA - Defense World
FY2025 EPS Estimates for RNA Lowered by Cantor Fitzgerald - Defense World
When (RNA) Moves Investors should Listen - news.stocktradersdaily.com
Avidity Biosciences Reports Q1 2025 Earnings - TipRanks
Transcript : Avidity Biosciences, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 03 - marketscreener.com
Avidity Biosciences (NASDAQ:RNA) Price Target Cut to $68.00 by Analysts at HC Wainwright - Defense World
Avidity Biosciences to Participate in Upcoming Investor Conference - Kilgore News Herald
Avidity Biosciences (RNA) Target Price Lowered by HC Wainwright & Co. | RNA Stock News - GuruFocus
Avidity Biosciences Announces Upcoming Presentations at 2023 Myo - GuruFocus
Avidity Biosciences First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Avidity Biosciences’ (RNA) Buy Rating Reiterated at Chardan Capital - Defense World
Avidity Biosciences (RNA) Receives Buy Rating from Chardan Capital | RNA Stock News - GuruFocus
Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights - BioSpace
Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
12 Analysts Assess Avidity Biosciences: What You Need To Know - Benzinga
RNA Therapeutics Pioneer Avidity Biosciences Takes Stage at Major Bank of America Healthcare Conference - Stock Titan
(RNA) Investment Report - news.stocktradersdaily.com
Avidity Biosciences chief program officer sells $190k in stock By Investing.com - Investing.com South Africa
Avidity Biosciences chief program officer sells $190k in stock - Investing.com Australia
Envestnet Asset Management Inc. Lowers Position in Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World
Avidity Biosciences appoints Deloitte as new auditor By Investing.com - Investing.com Canada
Avidity Biosciences appoints Deloitte as new auditor - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Avidity Biosciences' RNA Drug for DM1 Gains Orphan Status in Jap - GuruFocus
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Financial Times
Federated Hermes Inc. Decreases Stake in Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World
Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 (PR Newswire) - Aktiellt
Avidity’s del-desiran for DM1 named orphan drug in Japan - Muscular Dystrophy News
Beyond The Numbers: 13 Analysts Discuss Avidity Biosciences Stock - Benzinga
Japan grants Avidity’s DM1 drug Orphan status By Investing.com - Investing.com South Africa
Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 - StreetInsider
Avidity Biosciences Receives Orphan Drug Designation in Japan fo - GuruFocus
Avidity Says Japan Grants Orphan Drug Status to Del-Desiran for Myotonic Dystrophy Type 1 - marketscreener.com
Japan grants Avidity's DM1 drug Orphan status By Investing.com - Investing.com India
Japan grants Avidity's DM1 drug Orphan status - Investing.com
Avidity Biosciences Receives Orphan Drug Designation In Japan For Delpacibart Etedesiran - MarketScreener
Myotonic Dystrophy Pipeline Analysis and Clinical Trials - openPR.com
Avidity Biosciences chief program officer sells shares worth $206,799 - MSN
Avidity Biosciences CFO sells $93,985 in stock - MSN
Avidity Biosciences (RNA): Among Unstoppable Stocks That Could Double Your Money - MSN
Avidity Biosciences’ chief program officer sells $163k in stock - Investing.com India
Avidity Biosciences’ chief program officer sells $163k in stock By Investing.com - Investing.com UK
Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock? - Nasdaq
17.27%
1.06%
자본화:
|
볼륨(24시간):